- PureTech Health noted that affiliate company Karuna Therapeutics met its primary goal in a clinical trial of a treatment of acute psychosis in patients with schizophrenia.

The treatment, called, KarXT, demonstrated a statistically significant and clinically meaningful 11.6 point mean reduction in total Positive and Negative Syndrome Scale (PANSS) score compared to placebo.

It also demonstrated good overall tolerability.

A statistically significant reduction in the secondary endpoints of PANSS-Positive and PANSS-Negative scores were also observed.

'These impressive results are another important validation of PureTech's innovation engine that has generated highly differentiated platforms to address serious diseases,' PureTech chief executive Daphne Zohar said.

'It is very exciting to see Karuna reach this important milestone with its lead candidate KarXT that originated at PureTech.'

'KarXT is now being advanced by one of the leading CNS drug development teams and has the potential to be the first novel therapeutic approach in decades to treat psychosis in patients with schizophrenia and Alzheimer's disease.'

At 1:01pm: [LON:PRTC] PureTech Health Plc share price was +3p at 222p

Story provided by